Allergic Rhinitis
Allergic rhinitis, also known as hay fever when seasonal, is an inflammatory condition in the nose caused by the immune system's overreaction to airborne allergens, characterized by symptoms such as runny or stuffy nose, sneezing, itchy and watery eyes, and sinus congestion. Symptom onset is rapid after allergen exposure and can impact sleep, work, and study, with many affected individuals also experiencing asthma, allergic conjunctivitis, or atopic dermatitis.
Health Outcomes
- Absence of Adverse Physiological Effects
- Absence of Serious Symptoms such as Septic Shock
- Absence of Treatment-Related Side Effects
- Accelerated Immune Response Maturation
- Accelerated Oral Tolerance Development
- Activated Immune Response
- Altered IL-4 Levels
- Altered Microbial Composition
- Altered TH1/TH2 Immune Response
- Asymptomatic or Mild Symptoms
- Elevated Serum IgE Levels
- Elevated Serum Total Ig Levels
- Enhanced Goblet Cell Function
- Enhanced Immune Response (Higher IL-4 Levels)
- Enhanced Infant Gut Microbiota by Bifidobacterium lactis
- Enhanced Mucosal Immune Function
- Enhanced Type 2 Helper T Cell Response
- Good Tolerability
- Improved Airway Allergic Inflammation
- Improved Airway Immune Response
- Improved Airway Mucosa Condition
- Improved Allergic Immune Responses
- Improved Allergic Inflammation Markers
- Improved Allergic Outcomes
- Improved Allergic Rhinitis Total Effective Rate
- Improved Allergic Symptoms
- Improved Allergy Effectiveness
- Improved Anti-Allergy-Related Cytokine Profile
- Improved Antiallergic Function
- Improved Asthmatic Condition
- Improved Atopic Dermatitis
- Improved Atopic Dermatitis Symptoms
- Improved Cedar Pollinosis Symptoms
- Improved Health in Children with Allergies
- Improved Humoral Immune Parameters
- Improved Immune Balance
- Improved Immune Tolerance
- Improved Immunoglobulin A Production
- Improved Immunoglobulin Levels
- Improved Nasal Histopathology
- Improved Nasal Mucosa Histology
- Improved Nasal Symptoms in Perennial Allergic Rhinitis
- Improved Overall Symptom Score
- Improved Quality of Life for Eye, Nose, and Throat Symptoms
- Improved Respiratory Immune Function
- Improved Respiratory Immunity
- Improved Rhinoconjunctivitis-Specific Quality of Life
- Improved Symptom Control
- Improved Symptom Score
- Improved Work Performance
- Increased Antibody Secretion to Beta-Lactoglobulin
- Increased Antigen-Specific IgG1 Levels
- Increased Bifidobacterium longum Relative Abundance
- Increased Cytokine Secretion
- Increased Eosinophil Count
- Increased Epithelial-Derived IgG Levels
- Increased Histamine Production
- Increased Immune Response
- Increased Immunoglobulin A (IgA)-Positive Cells
- Increased Immunoglobulin A Levels in Breast Milk
- Increased Immunoglobulin Levels
- Increased Incidence of Upper Respiratory Symptoms
- Increased Indigenous Bifidobacterium Levels
- Increased Levels of Bifidobacteria
- Increased Mast Cells in Mucosal Tissues
- Increased Mucin Production
- Increased Mucin Secretion
- Increased Mucosal B-Cell Responses
- Increased Nitric Oxide Level
- Increased OVA-specific IgG Levels Upon Immunization
- Increased Presence of Bifidobacterium lactis
- Increased Production of Anti-inflammatory Cytokine IL-10
- Increased Production of Anti-inflammatory Histamine
- Increased Respiratory Sensitization
- Increased Salivary IgA Levels
- Increased Secretory IgA Level
- Increased Secretory Immunoglobulin A
- Increased Serum Immunoglobulin Levels
- Increased Th2 Cytokines Production
- Long-Lasting Immunomodulatory Effects After Weaning
- Maintained Mucosa-Associated Immunity
- Modulated Immune Markers
- Modulated Immune System
- Modulated Immunological Profile
- Modulated Systemic Th1/Th2 Balance
- Modulated Upper Airway Immune Response
- No Adverse Effects
- No Effect on Growth Parameters
- No Improvement in Allergy Symptoms
- No Improvement in Apple Food Allergy Symptoms
- No Improvement in Birch-Pollen Allergy Symptoms
- No Increase in Adverse Effects
- No Mutagenicity, Teratogenicity, or Genotoxicity
- No Reduction in Atopic Dermatitis Severity
- No Significant Change in IgE Levels
- No Significant Change in Inflammatory Responses
- No Significant Effect on Liver Enzymes
- No Significant Increase in Adverse Effects
- No Significant Reduction in Atopic Dermatitis Severity
- Prevented Allergic Reactions
- Prevention of Mucus Barrier Decline
- Rebalanced Th1/Th2/Th17 Cell Ratios
- Reduced Activation of CD63 Expressing Basophils
- Reduced Airway Pathological Responses
- Reduced Airway T Helper Type 2 Cytokines
- Reduced Allergen Hyperreactivity
- Reduced Allergic Diseases
- Reduced Allergic Disorders
- Reduced Allergic Inflammatory Response
- Reduced Allergic Markers
- Reduced Allergic Reaction Risk
- Reduced Allergic Reactions
- Reduced Allergic Responses
- Reduced Allergic Rhinitis Symptom Episode Per Day
- Reduced Allergic Scores
- Reduced Allergic Symptoms
- Reduced Antigen-Specific IgE Levels
- Reduced Atopic Diseases
- Reduced Bloody Nasal Mucus
- Reduced Common Cold Incidence in Susceptible Populations
- Reduced Conjunctival Congestion Score
- Reduced Day School Absenteeism
- Reduced Days with Runny Nose Symptoms
- Reduced Disease Symptoms
- Reduced Disruption of Normal Activities Due to Allergies
- Reduced Duration of Nasal Symptoms
- Reduced Egg Allergy
- Reduced Egg White Sensitization
- Reduced Eosinophil Count
- Reduced Eosinophil Infiltration
- Reduced Eosinophil Peroxidase Levels
- Reduced Eosinophilic Inflammation
- Reduced Exacerbation of Chronic Adenoiditis
- Reduced Frequency of Upper Respiratory Tract Infections
- Reduced HDM-Specific IgG1 Levels
- Reduced Hay Fever Prevalence
- Reduced Histamine Release
- Reduced Hypersensitivity Responses
- Reduced IL-4 Levels
- Reduced IL-4 Secretion
- Reduced IL-4 Secretion from Naïve T Cells
- Reduced IL-5 Levels
- Reduced IL-9 Levels
- Reduced IgE Levels
- Reduced IgE Production
- Reduced Immunoglobulin E Production
- Reduced Incidence Rate of URTIs
- Reduced Incidence of Allergic Manifestations
- Reduced Incidence of Milk Allergy
- Reduced Infant Allergies
- Reduced Infant Atopic Eczema and Allergic Disease
- Reduced Inflammatory Activities
- Reduced Inflammatory Diseases
- Reduced Itchy Nose
- Reduced Lifetime Prevalence of Atopic Sensitization
- Reduced Local Immunoglobulin Production
- Reduced Medication Use for Allergies
- Reduced Mold Presence
- Reduced Nasal Congestion
- Reduced Nasal Inflammation
- Reduced Nasal Mucosa Neutrophil Infiltration
- Reduced Nasal Stuffiness
- Reduced Nasal Symptom Score
- Reduced Nasal Symptoms
- Reduced OVA-Specific Antibodies
- Reduced Ocular Symptom Score
- Reduced Ocular Symptoms of Allergy
- Reduced Ocular Symptoms of Japanese Cedar Pollinosis
- Reduced Otitis Media Episode Incidence
- Reduced Ovalbumin-Specific IgE Level
- Reduced Ovalbumin-Specific IgE Production
- Reduced Overall Symptom Score
- Reduced Pathological Symptoms
- Reduced Prevalence of Atopic Sensitization
- Reduced Prevalence of Rhinoconjunctivitis
- Reduced Pro-inflammatory Mediator Levels
- Reduced Proinflammatory Mediators
- Reduced Red Eye Duration
- Reduced Respiratory Symptom Days
- Reduced Respiratory Symptoms
- Reduced Rhinitis
- Reduced Rhinitis Prevalence
- Reduced Risk of Colorectal Cancer
- Reduced Risk of Multiple Sclerosis
- Reduced Risk of Sensitization in Infants
- Reduced Runny Nose Duration
- Reduced Secretion Consistency
- Reduced Serum IL-4 Levels
- Reduced Serum IgE Levels
- Reduced Serum Immunoglobulin E Levels
- Reduced Serum OVA-specific IgE Levels
- Reduced Serum OVA-specific IgG1 Levels
- Reduced Severity of Nasal Congestion and Runny Nose
- Reduced Sneezing Symptoms
- Reduced Susceptibility to Inflammatory Exposure
- Reduced Symptoms
- Reduced Symptoms of Birch-pollen Allergy
- Reduced Symptoms of Perennial Allergic Rhinitis
- Reduced Systemic Anaphylaxis
- Reduced Th-2 Cytokine Concentrations
- Reduced Th1/Th2 Ratio
- Reduced Th2 Cytokine Levels
- Reduced Th2 Cytokine Production
- Reduced Th2 Immunity
- Reduced Th2 Reactions
- Reduced Th2 Response
- Reduced Total IgE Levels
- Reduced Total Nasal Symptom Score
- Reduced Total Symptom Score
- Reduced Treatment Duration
- Reduced Upper Respiratory Symptoms
- Reduced Use of Rescue Medication
- Regulated Inflammatory Cytokines
- Restored Th1/Th2 Cytokine Balance
- Safe Drug Administration
- Safe for Consumption with No Adverse Immune Effects
- Symptom Alleviation
- Unchanged Apple-Induced Symptoms
- Unchanged Immune Parameters
- Unchanged Inflammatory Response
- Well Tolerated Treatment